Beijing Puqi Pharmaceutical Technology
Develops and issues pharmaceutical products with a focus on innovative medical solutions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | CNY300m | Series B | |
| Total Funding | 000k | ||
Related Content
Established in 2016, Beijing Puqi Pharmaceutical Technology, also known as PrimeGene (Beijing), operates as a privately held pharmaceutical company focused on drug discovery and development. The firm is strategically centered on creating new drugs for immune and inflammatory diseases, with a specific emphasis on treatments for skin, ophthalmology, rhinology, and respiratory system conditions. The company's business model encompasses innovative drug research, the development of clinically valuable generic drugs, and pharmaceutical industrialization.
The company's core activities involve the research, development, and commercialization of a pipeline of pharmaceutical products. This drug pipeline includes small molecule drugs targeting immune system diseases, nervous system diseases, neoplasms, infectious diseases, and metabolic disorders. One of its notable drug candidates is Pumecitinib, a JAK tyrosine kinase inhibitor. The company is actively engaged in clinical trials to advance its products toward regulatory approval and market entry. The business generates revenue but is also backed by venture capital, having raised funds to support its R&D and commercialization efforts.
As a privately backed entity, Beijing Puqi Pharmaceutical Technology has secured funding from multiple investors. It has completed several funding rounds, including a Series B round in early 2025, to finance its operations and drug development programs. The company maintains a portfolio of patents related to its discoveries, such as polymorphs of JAK tyrosine kinase inhibitors and their preparation methods. Its client base would primarily consist of patients and healthcare providers upon successful commercialization of its drug candidates, operating within the global biopharmaceutical market. Its main office is located in the Fengtai District of Beijing.
Keywords: drug discovery, pharmaceutical development, Beijing Puqi, PrimeGene Beijing, innovative drugs, generic drugs, immune diseases, inflammatory diseases, ophthalmology drugs, respiratory treatments, clinical trials, small molecule drugs, Pumecitinib, JAK inhibitor, venture capital backed, biopharmaceutical, pharmaceutical R&D, drug commercialization, skin disease treatment, rhinology treatments